MedWatch

Nanovi submits cancer biomarker for marketing approval in the US

Danish firm Nanovi has submitted its leading product, a biomarker for cancer therapies, for approval on the world’s biggest cancer market, where it has the potential to break new ground, says CEO Jesper Boysen.

Jesper Boysen, CEO of Nanovi | Photo: Nanovi / PR

Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs